JP2022542140A - 阻害剤化合物 - Google Patents

阻害剤化合物 Download PDF

Info

Publication number
JP2022542140A
JP2022542140A JP2022505207A JP2022505207A JP2022542140A JP 2022542140 A JP2022542140 A JP 2022542140A JP 2022505207 A JP2022505207 A JP 2022505207A JP 2022505207 A JP2022505207 A JP 2022505207A JP 2022542140 A JP2022542140 A JP 2022542140A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
trifluoromethyl
phenyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022505207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542140A5 (https=
JPWO2021012018A5 (https=
Inventor
フリン，バーナード・ルーク
レ，ジャン
ヤン，シューシン
Original Assignee
シンセラ・セラピューティクス・プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902614A external-priority patent/AU2019902614A0/en
Application filed by シンセラ・セラピューティクス・プロプライエタリー・リミテッド filed Critical シンセラ・セラピューティクス・プロプライエタリー・リミテッド
Publication of JP2022542140A publication Critical patent/JP2022542140A/ja
Publication of JP2022542140A5 publication Critical patent/JP2022542140A5/ja
Publication of JPWO2021012018A5 publication Critical patent/JPWO2021012018A5/ja
Priority to JP2025100363A priority Critical patent/JP2025134819A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022505207A 2019-07-24 2020-07-24 阻害剤化合物 Pending JP2022542140A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025100363A JP2025134819A (ja) 2019-07-24 2025-06-16 阻害剤化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902614 2019-07-24
AU2019902614A AU2019902614A0 (en) 2019-07-24 Inhibitor compounds
PCT/AU2020/050763 WO2021012018A1 (en) 2019-07-24 2020-07-24 Inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025100363A Division JP2025134819A (ja) 2019-07-24 2025-06-16 阻害剤化合物

Publications (3)

Publication Number Publication Date
JP2022542140A true JP2022542140A (ja) 2022-09-29
JP2022542140A5 JP2022542140A5 (https=) 2023-07-31
JPWO2021012018A5 JPWO2021012018A5 (https=) 2023-07-31

Family

ID=74192564

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022505207A Pending JP2022542140A (ja) 2019-07-24 2020-07-24 阻害剤化合物
JP2025100363A Pending JP2025134819A (ja) 2019-07-24 2025-06-16 阻害剤化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025100363A Pending JP2025134819A (ja) 2019-07-24 2025-06-16 阻害剤化合物

Country Status (11)

Country Link
US (2) US12448371B2 (https=)
EP (1) EP4003986A4 (https=)
JP (2) JP2022542140A (https=)
KR (1) KR20220041843A (https=)
CN (1) CN114450281B (https=)
AU (1) AU2020316243A1 (https=)
BR (1) BR112022001270A2 (https=)
CA (1) CA3144506A1 (https=)
IL (1) IL290087B1 (https=)
MX (1) MX2022000845A (https=)
WO (1) WO2021012018A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202213792D0 (en) * 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
US11912675B1 (en) 2023-10-11 2024-02-27 King Faisal University N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11919872B1 (en) 2023-10-11 2024-03-05 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11891366B1 (en) 2023-10-12 2024-02-06 King Faisal University 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11999706B1 (en) 2023-10-13 2024-06-04 King Faisal University 4-chloro-N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527958A (ja) * 2007-05-22 2010-08-19 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターとして有用なベンズアミド
WO2012164103A2 (en) * 2011-06-03 2012-12-06 Universität Zürich Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair
WO2015155738A2 (en) * 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP2017526733A (ja) * 2014-06-26 2017-09-14 モナシュ ユニヴァーシティ 酵素相互作用薬剤
CN108079303A (zh) * 2017-12-14 2018-05-29 广东药科大学 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用
WO2018112077A1 (en) * 2016-12-13 2018-06-21 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2923661A (en) 1957-03-22 1960-02-02 Irwin Neisler And Co N-[2-(1-phenyl-propyl)]-2, 2, 2-trichloroethylidenimine
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
FI982268L (fi) 1998-10-20 2000-04-21 Tomi Jaervinen Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen uudet pro drugit, niiden valmistus ja käyttö

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527958A (ja) * 2007-05-22 2010-08-19 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターとして有用なベンズアミド
WO2012164103A2 (en) * 2011-06-03 2012-12-06 Universität Zürich Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair
WO2015155738A2 (en) * 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP2017526733A (ja) * 2014-06-26 2017-09-14 モナシュ ユニヴァーシティ 酵素相互作用薬剤
WO2018112077A1 (en) * 2016-12-13 2018-06-21 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
CN108079303A (zh) * 2017-12-14 2018-05-29 广东药科大学 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AURELIO, LUIGI ET AL.: "From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59(3), JPN7024002588, 2016, pages 965 - 984, ISSN: 0005528561 *
KRETSCHMER, SIMON B. M. ET AL.: "Development of novel aminothiazole-comprising 5-LO inhibitors", FUTURE MEDICINAL CHEMISTRY, vol. 8(2), JPN7024002591, 2016, pages 149 - 164, ISSN: 0005349280 *
PARK, SANG WON ET AL.: "Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-a-in", MEDCHEMCOMM, vol. 9(8), JPN7024002590, 2018, pages 1305 - 1310, ISSN: 0005349279 *
RAJAK, HARISH ET AL.: "2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21(19), JPN7024002589, 2011, pages 5735 - 5738, ISSN: 0005349278 *
野崎正勝 等, 創薬化学, vol. 第１版, JPN6012059719, 1995, pages 98 - 99, ISSN: 0005528562 *

Also Published As

Publication number Publication date
AU2020316243A1 (en) 2022-03-03
BR112022001270A2 (pt) 2022-06-14
CN114450281A (zh) 2022-05-06
EP4003986A1 (en) 2022-06-01
IL290087B1 (en) 2026-01-01
EP4003986A4 (en) 2023-03-01
US20220274970A1 (en) 2022-09-01
JP2025134819A (ja) 2025-09-17
KR20220041843A (ko) 2022-04-01
WO2021012018A1 (en) 2021-01-28
US20260001870A1 (en) 2026-01-01
US12448371B2 (en) 2025-10-21
IL290087A (en) 2022-03-01
MX2022000845A (es) 2022-04-20
CN114450281B (zh) 2024-08-16
CA3144506A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US20260001870A1 (en) Inhibitor compounds
US8217065B2 (en) Organic compounds
CN110156770B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
JP6853619B2 (ja) シアノトリアゾール化合物の医薬用途
JP4637578B2 (ja) 代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類
AU2002349754B2 (en) Novel 1,2,4-triazole compound
US20050075375A1 (en) Heterocyclic compounds for treating hepatitis C virus
TWI808305B (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
JP2006500362A (ja) 置換ピロロピリジン類
US20050288515A1 (en) Chemical compounds
KR20090086623A (ko) 스테아로일-코엔자임 ａ 델타-9 디세츄라제의 억제제로서의 아자사이클로알칸 유도체
AU2007265965B2 (en) Pyridylisoxazole derivative
WO2009041972A1 (en) Antibacterial compounds and methods of using same
EP4077290A1 (en) 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders
US20100261673A1 (en) Antibacterial compounds and methods of using same
US20070142437A1 (en) Chemical compounds
AU2020264679B2 (en) Selective ligands of human constitutive androstane receptor
CZ34975U1 (cs) Ligandy lidského konstitutivního adrostanového receptoru
KR20070018006A (ko) 헤테로폴리시클릭 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250217